1. Home
  2. BCAB vs SPRU Comparison

BCAB vs SPRU Comparison

Compare BCAB & SPRU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • SPRU
  • Stock Information
  • Founded
  • BCAB 2007
  • SPRU 2008
  • Country
  • BCAB United States
  • SPRU United States
  • Employees
  • BCAB N/A
  • SPRU N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • SPRU Auto Parts:O.E.M.
  • Sector
  • BCAB Health Care
  • SPRU Consumer Discretionary
  • Exchange
  • BCAB Nasdaq
  • SPRU Nasdaq
  • Market Cap
  • BCAB 31.5M
  • SPRU 34.9M
  • IPO Year
  • BCAB 2020
  • SPRU N/A
  • Fundamental
  • Price
  • BCAB $0.68
  • SPRU $1.76
  • Analyst Decision
  • BCAB Hold
  • SPRU
  • Analyst Count
  • BCAB 3
  • SPRU 0
  • Target Price
  • BCAB $1.00
  • SPRU N/A
  • AVG Volume (30 Days)
  • BCAB 1.1M
  • SPRU 105.2K
  • Earning Date
  • BCAB 11-06-2025
  • SPRU 11-12-2025
  • Dividend Yield
  • BCAB N/A
  • SPRU N/A
  • EPS Growth
  • BCAB N/A
  • SPRU N/A
  • EPS
  • BCAB N/A
  • SPRU N/A
  • Revenue
  • BCAB $11,000,000.00
  • SPRU $98,396,000.00
  • Revenue This Year
  • BCAB N/A
  • SPRU $2.12
  • Revenue Next Year
  • BCAB N/A
  • SPRU N/A
  • P/E Ratio
  • BCAB N/A
  • SPRU N/A
  • Revenue Growth
  • BCAB N/A
  • SPRU 23.43
  • 52 Week Low
  • BCAB $0.24
  • SPRU $1.13
  • 52 Week High
  • BCAB $2.53
  • SPRU $3.25
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 63.71
  • SPRU 65.52
  • Support Level
  • BCAB $0.60
  • SPRU $1.47
  • Resistance Level
  • BCAB $0.84
  • SPRU $1.71
  • Average True Range (ATR)
  • BCAB 0.08
  • SPRU 0.09
  • MACD
  • BCAB 0.02
  • SPRU 0.03
  • Stochastic Oscillator
  • BCAB 62.14
  • SPRU 80.49

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About SPRU Spruce Power Holding Corporation

Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.

Share on Social Networks: